Literature DB >> 22552256

Response inhibition and psychomotor speed during methadone maintenance: impact of treatment duration, dose, and sleep deprivation.

B K Bracken1, G H Trksak, D M Penetar, W L Tartarini, M A Maywalt, C M Dorsey, S E Lukas.   

Abstract

BACKGROUND: In opiate-dependent individuals, abstinence results in deficits in cognitive functioning, which may be exacerbated by medication-associated sleep disruption.
METHOD: To assess cognitive function and the influence of sleep deprivation (SD), 14 healthy control (HC) and 22 methadone maintained (MM) participants completed the continuous performance task (CPT) after a baseline night, a night of total SD, and two recovery sleep nights. The digit symbol substitution task (DSST) was administered at bedtime and in the morning. Secondary analyses separated MM participants into short- (< 12 months; n=8) and long-term (≥ 12 months; n=14) treatment duration groups, and into low- (< 80 mg; n=9) and high-dose (≥ 80 mg; n=13) groups.
RESULTS: Linear mixed model ANOVAs revealed that there was no effect of SD. Across all days MM participants had more errors of omission, fewer correct responses, and slower reaction times (RTs) on the CPT, and fewer accurate substitutions on the evening and morning DSST. Short-term MM participants exhibited slower RTs on the CPT, and fewer correct substitutions on the evening DSST compared to long-term MM participants. Low-dose MM participants had slower RTs on the CPT than HCs and high-dose MM participants.
CONCLUSION: These data demonstrate that methadone-maintained individuals exhibit poorer performance on tasks of psychomotor speed and selective attention/impulsivity, but with longer-term treatment, performance appears to return toward control levels. Furthermore, while one day of SD was enough to alter subjective reports of sleep quality, cognitive function may be more resilient.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22552256      PMCID: PMC3419309          DOI: 10.1016/j.drugalcdep.2012.04.004

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  34 in total

Review 1.  Opioids, sleep architecture and sleep-disordered breathing.

Authors:  David Wang; Harry Teichtahl
Journal:  Sleep Med Rev       Date:  2006-12-01       Impact factor: 11.609

2.  No change of sleep after 6 and 12 months of methadone maintenance treatment.

Authors:  Einat Peles; Shaul Schreiber; Rachel Bar Hamburger; Miriam Adelson
Journal:  J Addict Med       Date:  2011-06       Impact factor: 3.702

3.  Cognitive impairment among methadone maintenance patients.

Authors:  S Darke; J Sims; S McDonald; W Wickes
Journal:  Addiction       Date:  2000-05       Impact factor: 6.526

4.  Diacetylmorphine versus methadone for the treatment of opioid addiction.

Authors:  Eugenia Oviedo-Joekes; Suzanne Brissette; David C Marsh; Pierre Lauzon; Daphne Guh; Aslam Anis; Martin T Schechter
Journal:  N Engl J Med       Date:  2009-08-20       Impact factor: 91.245

5.  Polysomnographic and subjective sleep predictors of alcoholic relapse.

Authors:  K J Brower; M S Aldrich; J M Hall
Journal:  Alcohol Clin Exp Res       Date:  1998-11       Impact factor: 3.455

6.  Cognitive functioning during methadone and buprenorphine treatment: results of a randomized clinical trial.

Authors:  Michael Soyka; Martin Lieb; Sabine Kagerer; Christina Zingg; Gabriele Koller; Peter Lehnert; Claudia Limmer; Heinrich Kuefner; Kristina Hennig-Fast
Journal:  J Clin Psychopharmacol       Date:  2008-12       Impact factor: 3.153

Review 7.  Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.

Authors:  Richard P Mattick; Courtney Breen; Jo Kimber; Marina Davoli
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08

8.  Human performance under sustained operations and acute sleep deprivation conditions: toward a model of controlled attention.

Authors:  June J Pilcher; David Band; Heather N Odle-Dusseau; Eric R Muth
Journal:  Aviat Space Environ Med       Date:  2007-05

9.  Profiles of cognitive dysfunction in chronic amphetamine and heroin abusers.

Authors:  T J Ornstein; J L Iddon; A M Baldacchino; B J Sahakian; M London; B J Everitt; T W Robbins
Journal:  Neuropsychopharmacology       Date:  2000-08       Impact factor: 7.853

10.  Methadone vs. buprenorphine/naloxone during early opioid substitution treatment: a naturalistic comparison of cognitive performance relative to healthy controls.

Authors:  Pekka Rapeli; Carola Fabritius; Hannu Alho; Mikko Salaspuro; Kristian Wahlbeck; Hely Kalska
Journal:  BMC Clin Pharmacol       Date:  2007-06-12
View more
  12 in total

1.  Longitudinal behavioral and fMRI-based assessment of inhibitory control in heroin addicts on methadone maintenance treatment.

Authors:  Jian-Jun Ye; Wei Li; Dong-Sheng Zhang; Qiang Li; Jia Zhu; Jia-Jie Chen; Yong-Bin Li; Xue-Jiao Yan; Jie-Rong Liu; Xuan Wei; Ya-Rong Wang; Wei Wang
Journal:  Exp Ther Med       Date:  2018-08-03       Impact factor: 2.447

2.  Sleep deprivation impairs performance in the 5-choice continuous performance test: similarities between humans and mice.

Authors:  Jordy van Enkhuizen; Dean Acheson; Victoria Risbrough; Sean Drummond; Mark A Geyer; Jared W Young
Journal:  Behav Brain Res       Date:  2013-12-12       Impact factor: 3.332

Review 3.  Characterizing the Interrelationships of Prescription Opioid and Benzodiazepine Drugs With Worker Health and Workplace Hazards.

Authors:  Michele Kowalski-McGraw; Judith Green-McKenzie; Sudha P Pandalai; Paul A Schulte
Journal:  J Occup Environ Med       Date:  2017-11       Impact factor: 2.162

4.  Cognitive performance in methadone maintenance patients: effects of time relative to dosing and maintenance dose level.

Authors:  Olga Rass; Bethea A Kleykamp; Ryan G Vandrey; George E Bigelow; Jeannie-Marie Leoutsakos; Maxine L Stitzer; Eric C Strain; Marc L Copersino; Miriam Z Mintzer
Journal:  Exp Clin Psychopharmacol       Date:  2014-02-17       Impact factor: 3.157

5.  Abnormal functional integration of thalamic low frequency oscillation in the BOLD signal after acute heroin treatment.

Authors:  Niklaus Denier; André Schmidt; Hana Gerber; Marc Vogel; Christian G Huber; Undine E Lang; Anita Riecher-Rossler; Gerhard A Wiesbeck; Ernst-Wilhelm Radue; Marc Walter; Stefan Borgwardt
Journal:  Hum Brain Mapp       Date:  2015-10-06       Impact factor: 5.038

6.  Effects of Mindfulness-Oriented Recovery Enhancement Versus Social Support on Negative Affective Interference During Inhibitory Control Among Opioid-Treated Chronic Pain Patients: A Pilot Mechanistic Study.

Authors:  Eric L Garland; Myranda A Bryan; Sarah E Priddy; Michael R Riquino; Brett Froeliger; Matthew O Howard
Journal:  Ann Behav Med       Date:  2019-08-29

7.  Low-dose add-on memantine treatment may improve cognitive performance and self-reported health conditions in opioid-dependent patients undergoing methadone-maintenance-therapy.

Authors:  Yun-Hsuan Chang; Shiou-Lan Chen; Sheng-Yu Lee; Po See Chen; Tzu-Yun Wang; I Hui Lee; Kao Chin Chen; Yen Kuang Yang; Jau-Shyong Hong; Ru-Band Lu
Journal:  Sci Rep       Date:  2015-05-19       Impact factor: 4.379

8.  Inferior frontal cortex modulation with an acute dose of heroin during cognitive control.

Authors:  André Schmidt; Marc Walter; Hana Gerber; Otto Schmid; Renata Smieskova; Kerstin Bendfeldt; Gerhard A Wiesbeck; Anita Riecher-Rössler; Undine E Lang; Katya Rubia; Philip McGuire; Stefan Borgwardt
Journal:  Neuropsychopharmacology       Date:  2013-05-15       Impact factor: 7.853

9.  Cognitive profiles in persons with opioid use disorder enrolled in methadone treatment.

Authors:  Victoria Sanborn; John Gunstad; Roman Shrestha; Colleen B Mistler; Michael M Copenhaver
Journal:  Appl Neuropsychol Adult       Date:  2020-05-28       Impact factor: 2.050

10.  Cognitive control in opioid dependence and methadone maintenance treatment.

Authors:  Ding-Lieh Liao; Cheng-Yi Huang; Sien Hu; Su-Chen Fang; Chi-Shin Wu; Wei-Ti Chen; Tony Szu-Hsien Lee; Pau-Chung Chen; Chiang-Shan R Li
Journal:  PLoS One       Date:  2014-04-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.